Sanofi Pasteur MSD vaccine venture ends

pharmafield logo - pharma news

Sanofi Pasteur and MSD have announced that they are to part ways and end their joint vaccines operations in Europe.

The companies plan to focus on pursuing their own growth strategies by independently integrating their respective European vaccine businesses into their operations. 

The joint venture, Sanofi Pasteur MSD, is owned on a 50/50 basis by the companies. It was created in 1994 to develop and commercialise vaccines from both companies’ pipelines to improve and promote public health in 19 European countries.

Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD’s development pipelines over the past 20 years.

In a joint statement, the companies said: “We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimise vaccine coverage. By bringing vaccines more rapidly to market, both companies would deliver greater value to all stakeholders.”

Sanofi Pasteur and MSD expect the project to be completed by the end of 2016, subject to local labour laws and regulations and regulatory approvals.